Gastromotal: Withdrawal of the marketing authorisation application


On 5 November 2007, INFAI, Institut für biomedizinische Analytik & NMR-Imaging GmbH officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Gastromotal, for in vivo diagnosis of solid-phase gastric half emptying time in gastric motility disorders.

  • List item

    Questions and answers on the withdrawal of the marketing application for Gastromotal (PDF/50.7 KB)

    First published: 16/11/2007
    Last updated: 16/11/2007

  • Key facts

    Product number
    Date of withdrawal
    Company making the application
    INFAI, Institut für biomedizinische Analytik NMR-Imaging GmbH
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating